Since endosome dysfunction occurs very early in the AD pathogenic process, therapies that turn Rab5 activity back to normal (e.g., via Rab5 therapeutic targeting strategies already discussed in Section 3.3). The gene discussed is RAB5A; the disease is Alzheimer disease.